Incidence and prevalence of gastric neuroendocrine tumors in patients with chronic atrophic autoimmune gastritis.
Atrophic gastritis
Autoimmune gastritis
Gastric neuroendocrine tumors
Gastrin
Journal
World journal of gastrointestinal oncology
ISSN: 1948-5204
Titre abrégé: World J Gastrointest Oncol
Pays: China
ID NLM: 101532470
Informations de publication
Date de publication:
15 Aug 2023
15 Aug 2023
Historique:
received:
04
06
2023
revised:
23
06
2023
accepted:
07
07
2023
medline:
4
9
2023
pubmed:
4
9
2023
entrez:
4
9
2023
Statut:
ppublish
Résumé
The incidence of type I gastric neuroendocrine neoplasms (gNENs) has increased significantly over the past 50 years. Although autoimmune gastritis (AIG) increases the likelihood of developing gNENs, the exact incidence and prevalence of this association remain unclear. To evaluate the incidence and prevalence of type I gNENs in a cohort of patients with a histological diagnosis of AIG. Patients with a histological diagnosis of AIG were enrolled between October 2020 and May 2022. Circulating levels of CgA and gastrin were assessed at enrollment. Included patients underwent regular endoscopic follow-up to detect gastric neoplastic lesions, enterochromaffin-like (ECL) cell hyperplasia, and the development of gNEN. We included 176 patients [142 women (80.7%), median age 64 years, interquartile range (IQR) 53-71 years] diagnosed with AIG between January 1990 and June 2022. At enrollment. One hundred and sixteen patients (65.9%) had ECL hyperplasia, of whom, 29.5% had simple/linear, 30.7% had micronodular, and 5.7% had macronodular type. The median follow-up time was 5 (3-7.5) years. After 1032 person-years, 33 patients developed a total of 50 type I gNENs, with an incidence rate of 0.057 person-years, corresponding to an annual cumulative incidence of 5.7%. Circulating CgA levels did not significantly differ between AIG patients who developed gNENs and those who did not. Conversely, gastrin levels were significantly higher in AIG patients who developed gNENs [median 992 pg/mL IQR = 449-1500 Type I gNENs are a significant complication in AIG. Gastrin's low diagnostic accuracy prevents it from serving as a marker for early diagnosis. Effective strategies for early detection and treatment are needed.
Sections du résumé
BACKGROUND
BACKGROUND
The incidence of type I gastric neuroendocrine neoplasms (gNENs) has increased significantly over the past 50 years. Although autoimmune gastritis (AIG) increases the likelihood of developing gNENs, the exact incidence and prevalence of this association remain unclear.
AIM
OBJECTIVE
To evaluate the incidence and prevalence of type I gNENs in a cohort of patients with a histological diagnosis of AIG.
METHODS
METHODS
Patients with a histological diagnosis of AIG were enrolled between October 2020 and May 2022. Circulating levels of CgA and gastrin were assessed at enrollment. Included patients underwent regular endoscopic follow-up to detect gastric neoplastic lesions, enterochromaffin-like (ECL) cell hyperplasia, and the development of gNEN.
RESULTS
RESULTS
We included 176 patients [142 women (80.7%), median age 64 years, interquartile range (IQR) 53-71 years] diagnosed with AIG between January 1990 and June 2022. At enrollment. One hundred and sixteen patients (65.9%) had ECL hyperplasia, of whom, 29.5% had simple/linear, 30.7% had micronodular, and 5.7% had macronodular type. The median follow-up time was 5 (3-7.5) years. After 1032 person-years, 33 patients developed a total of 50 type I gNENs, with an incidence rate of 0.057 person-years, corresponding to an annual cumulative incidence of 5.7%. Circulating CgA levels did not significantly differ between AIG patients who developed gNENs and those who did not. Conversely, gastrin levels were significantly higher in AIG patients who developed gNENs [median 992 pg/mL IQR = 449-1500
CONCLUSION
CONCLUSIONS
Type I gNENs are a significant complication in AIG. Gastrin's low diagnostic accuracy prevents it from serving as a marker for early diagnosis. Effective strategies for early detection and treatment are needed.
Identifiants
pubmed: 37663936
doi: 10.4251/wjgo.v15.i8.1451
pmc: PMC10473929
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1451-1460Informations de copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: Authors have nothing to declare.
Références
Aliment Pharmacol Ther. 2019 Dec;50(11-12):1172-1180
pubmed: 31621927
Gastroenterology. 2021 Oct;161(4):1325-1332.e7
pubmed: 34454714
Front Endocrinol (Lausanne). 2021 Nov 18;12:741887
pubmed: 34867785
Nat Rev Dis Primers. 2020 Jul 9;6(1):56
pubmed: 32647173
Eur J Surg Oncol. 2018 Oct;44(10):1628-1633
pubmed: 29983275
Eur J Endocrinol. 2005 Mar;152(3):443-8
pubmed: 15757862
World J Gastroenterol. 2020 Feb 7;26(5):466-477
pubmed: 32089624
Arch Pathol Lab Med. 2008 Apr;132(4):633-40
pubmed: 18384215
Gastric Cancer. 2020 Jul;23(4):591-599
pubmed: 32026156
Am J Gastroenterol. 2021 Sep 1;116(9):1859-1867
pubmed: 34313623
Neuroendocrinology. 2016;103(2):119-24
pubmed: 26784901
Gut Liver. 2013 May;7(3):303-10
pubmed: 23710311
BMC Gastroenterol. 2022 Feb 19;22(1):70
pubmed: 35183117
Baillieres Clin Gastroenterol. 1993 Mar;7(1):149-65
pubmed: 7682874
Histopathology. 2020 Jan;76(2):182-188
pubmed: 31433515
Dig Dis Sci. 1996 Jan;41(1):40-8
pubmed: 8565765
Gut. 2023 Jan;72(1):30-38
pubmed: 35772926
J Clin Med. 2022 Jun 19;11(12):
pubmed: 35743593
Endocrinol Nutr. 2013 Aug-Sep;60(7):386-95
pubmed: 23271036
Clin Gastroenterol Hepatol. 2015 Dec;13(13):2282-9.e1-4
pubmed: 26079040
Function (Oxf). 2021 Nov 26;3(1):zqab062
pubmed: 35330921
Arkh Patol. 2023;85(1):57-61
pubmed: 36785963
World J Gastrointest Oncol. 2020 Aug 15;12(8):791-807
pubmed: 32879660
Scand J Gastroenterol. 2022 Nov;57(11):1296-1303
pubmed: 35645153
Eur J Epidemiol. 2010 Jul;25(7):439-48
pubmed: 20585973
Endocrine. 2017 Jun;56(3):633-638
pubmed: 27592118
J Clin Med. 2022 Jun 30;11(13):
pubmed: 35807078
Dig Liver Dis. 2019 Dec;51(12):1725-1730
pubmed: 31405587
Nat Rev Gastroenterol Hepatol. 2013 Sep;10(9):529-41
pubmed: 23774773
Autoimmun Rev. 2019 Mar;18(3):215-222
pubmed: 30639639
Int J Mol Sci. 2017 Sep 27;18(10):
pubmed: 28953255
Biomedicines. 2023 Mar 09;11(3):
pubmed: 36979807
Gastrointest Endosc. 2010 Jun;71(7):1150-8
pubmed: 20381801
Aliment Pharmacol Ther. 2011 Jun;33(12):1361-9
pubmed: 21492197
World J Gastrointest Endosc. 2023 Mar 16;15(3):103-113
pubmed: 37034968
Gastric Cancer. 2018 Jul;21(4):579-587
pubmed: 29460004
Front Immunol. 2022 Jul 22;13:910077
pubmed: 35935934
Mod Pathol. 2023 Apr;36(4):100098
pubmed: 36913909
World J Clin Cases. 2021 Sep 26;9(27):7973-7985
pubmed: 34621854
Front Oncol. 2013 Jan 22;3:2
pubmed: 23346552
Dig Liver Dis. 2019 Oct;51(10):1456-1460
pubmed: 31175013
Eur J Gastroenterol Hepatol. 2001 Dec;13(12):1449-56
pubmed: 11742193
Folia Biol (Praha). 2011;57(5):173-81
pubmed: 22123459
Adv Med Sci. 2016 Sep;61(2):175-179
pubmed: 26918709
Scand J Gastroenterol. 2017 Feb;52(2):150-156
pubmed: 27652682
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Oct 25;24(10):849-853
pubmed: 34674458
Curr Oncol Rep. 2021 Mar 14;23(4):43
pubmed: 33719003
Am J Surg Pathol. 1996 Oct;20(10):1161-81
pubmed: 8827022
J Clin Med. 2023 Jan 30;12(3):
pubmed: 36769710
Digestion. 2021;102(6):878-886
pubmed: 33839721